Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. 2011

Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
State Key Laboratory for Molecular Virology and Genetic Engineering, Institute for Viral Disease Control and Prevention, China CDC, 155 Chang Bai Road, Chang Ping District, Beijing 102206, China.

BACKGROUND The incidence of dengue, an infectious disease caused by dengue virus (DENV), has dramatically increased around the world in recent decades and is becoming a severe public health threat. However, there is currently no specific treatment for dengue fever, and licensed vaccine against dengue is not available. Vaccination with virus-like particles (VLPs) has shown considerable promise for many viral diseases, but the effect of DENV VLPs to induce specific immune responses has not been adequately investigated. RESULTS By optimizing the expression plasmids, recombinant VLPs of four antigenically different DENV serotypes DENV1-4 were successfully produced in 293T cells. The vaccination effect of dengue VLPs in mice showed that monovalent VLPs of each serotype stimulated specific IgG responses and potent neutralizing antibodies against homotypic virus. Tetravalent VLPs efficiently enhanced specific IgG and neutralizing antibodies against all four serotypes of DENV. Moreover, vaccination with monovalent or tetravalent VLPs resulted in the induction of specific cytotoxic T cell responses. CONCLUSIONS Mammalian cell expressed dengue VLPs are capable to induce VLP-specific humoral and cellular immune responses in mice, and being a promising subunit vaccine candidate for prevention of dengue virus infection.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003716 Dengue Virus A species of the genus FLAVIVIRUS which causes an acute febrile and sometimes hemorrhagic disease in man. Dengue is mosquito-borne and four serotypes are known. Breakbone Fever Virus,Breakbone Fever Viruses,Dengue Viruses,Fever Virus, Breakbone,Fever Viruses, Breakbone,Virus, Breakbone Fever,Virus, Dengue,Viruses, Breakbone Fever,Viruses, Dengue
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
August 2001, Hepatology (Baltimore, Md.),
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
July 2004, Journal of virology,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
January 2018, PloS one,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
March 2020, Viruses,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
September 2003, Clinical immunology (Orlando, Fla.),
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
February 2006, Journal of virology,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
April 2017, Scientific reports,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
March 2012, Vaccine,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
May 2013, Archives of virology,
Shuo Zhang, and Mifang Liang, and Wen Gu, and Chuan Li, and Fang Miao, and Xiaofang Wang, and Cong Jin, and Li Zhang, and Fushun Zhang, and Quanfu Zhang, and Lifang Jiang, and Mengfeng Li, and Dexin Li
September 2014, Journal of virology,
Copied contents to your clipboard!